Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Full Article: https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1.full-text PDF: View ORCID ProfileAsaf Biber, Michal Mandelboim, Geva Harmelin, Dana Lev, Li Ram, Amit Shaham, Ital Nemet, Limor Kliker, Oran Erster, Eli Schwartz doi: https://doi.org/10.1101/2021.05.31.21258081 Abstract Background Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection. Methods The double-blinded trial compared patients receiving ivermectin 0·2 mg/kg for 3 days vs. placebo in non-hospitalized COVID-19 patients. … Read more